Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 4-phenoxy-3-pyrrolidin-1-yl-5-sulfamoylbenzoic Acid
2. Hoe 118
1. 55837-27-9
2. Tauliz
3. 4-phenoxy-3-pyrrolidin-1-yl-5-sulfamoylbenzoic Acid
4. Eurelix
5. Hoe 118
6. 4-phenoxy-3-(pyrrolidin-1-yl)-5-sulfamoylbenzoic Acid
7. Hoe-118
8. Benzoic Acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)-
9. S 73 4118
10. 4-phenoxy-3-(1-pyrrolidinyl)-5-sulfamoylbenzoic Acid
11. Dq6kk6gv93
12. Ncgc00016878-01
13. Arlix
14. Cas-55837-27-9
15. Dsstox_cid_3488
16. Dsstox_rid_77050
17. Dsstox_gsid_23488
18. S-734118
19. S-73-4118
20. Piretanido [spanish]
21. Piretanido
22. Piretanidum
23. Piretanidum [inn-latin]
24. Piretanido [inn-spanish]
25. Arelix (tn)
26. Einecs 259-852-9
27. Unii-dq6kk6gv93
28. Brn 5633965
29. Piretanide [usan:inn:ban:jan]
30. Piretanide-[d4]
31. S 734118
32. 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)-benzoic Acid
33. Piretanide [mi]
34. Piretanide [inn]
35. Piretanide [jan]
36. Acide Phenoxy-4-(1-pyrrolidinyl)-3-sulfamoyl-5 Benzoique [french]
37. Prestwick0_001047
38. Prestwick1_001047
39. Prestwick2_001047
40. Prestwick3_001047
41. Piretanide [usan]
42. Piretanide [mart.]
43. Piretanide [who-dd]
44. Schembl49473
45. Bspbio_000974
46. Mls002154123
47. Piretanide (jan/usan/inn)
48. Spbio_002907
49. Bpbio1_001072
50. Chembl349803
51. Gtpl4742
52. Dtxsid2023488
53. Chebi:32015
54. Piretanide For System Suitability
55. Acide Phenoxy-4-(1-pyrrolidinyl)-3-sulfamoyl-5 Benzoique
56. Piretanide [ep Monograph]
57. Hms1571a16
58. Hms2098a16
59. Hms2230g15
60. Hms3372o22
61. Hms3715a16
62. Zinc3812930
63. Tox21_110661
64. Akos015895445
65. Tox21_110661_1
66. Ccg-221047
67. Db02925
68. Ncgc00016878-02
69. Ncgc00016878-04
70. Smr001233430
71. Hy-119816
72. Ab00514020
73. Cs-0078068
74. Ft-0673944
75. 2-methyl-2-propylpropane-1,3-diyl Dicarbamate
76. D01634
77. 837p279
78. A924106
79. Sr-01000838837
80. 4-phenoxy-3-(pyrrolidinyl)-5-sulfamoylbenzoic Acid
81. Q3905617
82. Sr-01000838837-2
83. W-105543
84. 3-(1-pyrrolidinyl)-4-phenoxy-5-sulphamylbenzoic Acid
85. Brd-k87990216-001-03-7
86. 4-phenoxy-3-(1-pyrrolidinyl)-5-sulphamoylbenzoic Acid
87. F2173-0688
88. 3-(aminosulfonyl)-4-(phenyloxy)-5-pyrrolidin-1-ylbenzoic Acid
Molecular Weight | 362.4 g/mol |
---|---|
Molecular Formula | C17H18N2O5S |
XLogP3 | 2.2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 5 |
Exact Mass | 362.09364285 g/mol |
Monoisotopic Mass | 362.09364285 g/mol |
Topological Polar Surface Area | 118 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 564 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Diuretics
Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)
Sodium Potassium Chloride Symporter Inhibitors
Agents that inhibit SODIUM-POTASSIUM-CHLORIDE SYMPORTERS which are concentrated in the thick ascending limb at the junction of the LOOP OF HENLE and KIDNEY TUBULES, DISTAL. They act as DIURETICS. Excess use is associated with HYPOKALEMIA and HYPERGLYCEMIA. (See all compounds classified as Sodium Potassium Chloride Symporter Inhibitors.)
C - Cardiovascular system
C03 - Diuretics
C03C - High-ceiling diuretics
C03CA - Sulfonamides, plain
C03CA03 - Piretanide
Global Sales Information
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Piretanide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Piretanide, including repackagers and relabelers. The FDA regulates Piretanide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Piretanide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Piretanide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Piretanide supplier is an individual or a company that provides Piretanide active pharmaceutical ingredient (API) or Piretanide finished formulations upon request. The Piretanide suppliers may include Piretanide API manufacturers, exporters, distributors and traders.
click here to find a list of Piretanide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Piretanide CEP of the European Pharmacopoeia monograph is often referred to as a Piretanide Certificate of Suitability (COS). The purpose of a Piretanide CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Piretanide EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Piretanide to their clients by showing that a Piretanide CEP has been issued for it. The manufacturer submits a Piretanide CEP (COS) as part of the market authorization procedure, and it takes on the role of a Piretanide CEP holder for the record. Additionally, the data presented in the Piretanide CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Piretanide DMF.
A Piretanide CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Piretanide CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Piretanide suppliers with CEP (COS) on PharmaCompass.
Piretanide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Piretanide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Piretanide GMP manufacturer or Piretanide GMP API supplier for your needs.
A Piretanide CoA (Certificate of Analysis) is a formal document that attests to Piretanide's compliance with Piretanide specifications and serves as a tool for batch-level quality control.
Piretanide CoA mostly includes findings from lab analyses of a specific batch. For each Piretanide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Piretanide may be tested according to a variety of international standards, such as European Pharmacopoeia (Piretanide EP), Piretanide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Piretanide USP).
LOOKING FOR A SUPPLIER?